Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.51 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.51 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6150540 | 0.89 | KDM4E (0.58) | KDM4EPKMHPGDTPSAB1TPSD1 | |
| SCHEMBL1245476 | 0.84 | KDM4E (0.64) | KDM4EPKMHPGDNAMPTEPHX1 | |
| SCHEMBL24853346 | 0.84 | KDM4E (0.64) | KDM4EPKMHPGDNAMPTEPHX1 | |
| SCHEMBL6152939 | 0.84 | KDM4E (0.68) | KDM4EPKMHPGDEPHX1SMN1; SMN2 | |
| SCHEMBL5573225 | 0.84 | KDM4E (0.63) | KDM4EPKMHPGDEPHX1SMN1; SMN2 | |
| SCHEMBL13812320 | 0.83 | KDM4E (0.60) | KDM4EPKMHPGDEPHX1SMN1; SMN2 | |
| SCHEMBL31402457 | 0.83 | KDM4E (0.60) | KDM4EPKMHPGDEPHX1SMN1; SMN2 | |
| SCHEMBL3632843 | 0.83 | KDM4E (0.63) | KDM4EPKMHPGDNAMPTEPHX1 | |
| SCHEMBL21551407 | 0.83 | KDM4E (0.63) | KDM4EPKMHPGDEPHX1SMN1; SMN2 | |
| SCHEMBL21551436 | 0.83 | KDM4E (0.63) | KDM4EPKMHPGDEPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | KDM4E 470/4885PKM 3864/4885HPGD 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.